Top-News
Dienstag,
23.07.2024 06:45
von
PR Newswire
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Ein Stethoskop auf einem Schreibtisch mit Unterlagen. (Symbolfoto)
© SARINYAPINNGAM / iStock / Getty Images Plus / Getty Images
http://www.gettyimages.de
PR Newswire
SECAUCUS, N.J., July 23, 2024
- Second quarter revenues of $2.40 billion, up 2.5% from 2023
- Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023
- Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion; reported diluted EPS now expected to be between $7.57 and $7.77; and adjusted diluted EPS expected to be between $8.80 and $9.00
SECAUCUS, N.J., July 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2024.
"We delivered another strong quarter, with base business revenue growth of nearly 4% and total revenue growth of 2.5% as well as continued improvement in productivity and profitability in the base business," said Jim Davis, Chairman, CEO and President. "This performance is due to growth of new physician and hospital customers, more favorable test mix that includes greater adoption of advanced diagnostics and continued strength in healthcare utilization. We also made progress improving our operational quality and efficiency through greater use of automation and AI."
Mr. Davis added: "In addition, we are excited to announce four acquisitions that meet our criteria for growth, profitability and returns, and that will enable us to expand in strategic growth areas. Our planned acquisition of LifeLabs will position us to help this trusted lab leader grow and better serve Canada's growing and aging population. The acquisitions we recently announced of select outreach lab assets of Allina Health in Minnesota and Wisconsin and OhioHealth in Ohio reflect our ability to partner with high-quality health systems and extend our presence in key geographies. Our recently completed PathAI Diagnostics acquisition positions us to rapidly scale digital pathology innovation to help health systems and other providers improve cancer diagnoses."
| | Three Months Ended June 30, | | Six Months Ended June 30, | | ||||||||||
| | 2024 Anzeige Aktie im Fokus
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus! Kurse
| | 2023 | | Change | | 2024 | | 2023 | | Change | | ||
| | (dollars in millions, except per share data) | | ||||||||||||
| Reported: | | | | | | | | | | | | | ||
| Net revenues | $ 2,397 | | $ 2,338 | | 2.5 % | | $ 4,763 | | $ 4,669 | | 2.0 % | | ||
| Diagnostic Information Services revenues | $ 2,333 | | $ 2,268 | | 2.8 % | | $ 4,631 | | $ 4,527 | | 2.3 % | | ||
| Revenue per requisition | | | | | 1.6 % | | | | | | 0.9 % | | ||
| Requisition volume | | | | | 1.1 % | | | | | | 1.4 % | | ||
| Organic requisition volume | | | | | 0.7 % | | | | | | 0.9 % | | ||
| Operating income (a) | $ 355 | | $ 348 | | 1.9 % | | $ 655 | | $ 653 | | 0.2 % | | ||
| Operating income as a percentage of net revenues (a) | 14.8 % | | 14.9 % | | (0.1) % | | 13.7 % | | 14.0 % | | (0.3) % | | ||
| Net income attributable to Quest Diagnostics (a) | $ 229 | | $ 235 | | (2.4) % | | $ 423 | | $ 437 | | (3.1) % | | ||
| Diluted EPS (a) | $ 2.03 | | $ 2.05 | | (1.0) % | | $ 3.75 | | $ 3.83 | | (2.1) % | | ||
| Cash provided by operations | $ 360 | | $ 444 | | (18.9) % | | $ 514 | | $ 538 | | (4.4) % | | ||
| Capital expenditures | $ 92 | | $ 104 | | (10.8) % | | $ 196 | | $ 231 | | (14.9) % | | ||
| | | | | | | | | | | | | | ||
| Adjusted (a): | | | | | | | | | | | | | ||
| Operating income | $ 398 | | $ 389 | | 2.1 % | | $ 747 | | $ 739 | | 1.0 % | | ||
| Operating income as a percentage of net revenues | 16.6 % | | 16.7 % | | (0.1) % | | 15.7 % | | 15.8 % | | (0.1) % | | ||
| Net income attributable to Quest Diagnostics | $ 266 | | $ 263 | | 1.4 % Werbung Mehr Nachrichten zur Quest Diagnostics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | |||||||||
